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Abstract: In recent years, much progress has been made in pharmacotherapy for pediatric obsessive-compulsive disorder (OCD)
and chronic tic disorders (CTDs). What were previously considered relatively intractable conditions now have an array of efficacious
medicinal (and psychosocial) interventions available at clinicians’ disposal, including selective serotonin reuptake inhibitors, atypical
antipsychotics, and alpha-2 agonists. The purpose of this review is to discuss the evidence base for pharmacotherapy with pediatric OCD
and CTDs with regard to efficacy, tolerability, and safety, and to put this evidence in the context of clinical management in integrated
behavioral healthcare. While there is no single panacea for these disorders, there are a variety of medications that provide considerable
relief for children with these disabling conditions.
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Introduction

Obsessive-compulsive disorder (OCD) and chronic
tic disorders (CTDs) can be highly impairing conditions which affect a wide range of youth. Multiple
prevalence estimates for children and adolescents
indicate that approximately 1%–2% of children experience OCD, 0.5%–1.0% experience Tourette Disorder, 1.0%–2.0% experience chronic tic disorders and
approximately 5% experience transient tic disorders.1–7
Obsessive-compulsive disorder is characterized by
unwanted intrusive cognitions that persist against the
patient’s wishes (obsessions) followed by repetitive
behaviors intended to reduce associated distress (compulsions), which can be variably expressed.8–10 The
content of obsessions often includes perceived contamination, uncertainty about completing an action
(eg, checking locks), taboo thoughts (ie, sexual, religious, aggressive), and symmetry and ordering obsessions. Common compulsions include excessive hand
washing, repetitive touching of objects, covert rituals
(eg, counting, praying), reassurance seeking, unnecessary checking to ensure tasks have been completed,
and ordering of objects in a certain configuration until
they are perceived as “in order”. Tic disorders are
characterized by both simple and complex tics, which
are often manifest themselves through motor actions
(eg, eye-blinking, shoulder shrugging, or detailed
facial gestures) and verbal expressions (eg, groaning,
cursing in public despite no intention of doing so).
Tic disorders encompass chronic tic disorder (CTD),
transient tic disorder (TTD), and Tourette Disorder
(TD); CTDs (motor or verbal) are often grouped with
TD in treatment trials and in conceptualization of
pathology, whereas transient tic disorder has received
less focus in clinical research. Thus, this review will
address CTD and TD under the umbrella of CTDs.
Obsessive-compulsive disorder and CTDs share similarities in phenotypes and neurobiology and are commonly comorbid: a modest amount of children with
a principal diagnosis of OCD experience comorbid
tics (20%–40%), while a higher percentage of youth
with tics experience comorbid OCD (20%–60%).11–17
Comorbid tics are more frequent in younger OCD
patients, and both disorder classes are more prevalent
in younger boys.18
Obsessive-compulsive disorder and CTDs interfere with the child’s functioning in the school,
interpersonal, emotional, and home domains.19–28
126

In clinical samples, over half of patients with
both conditions have been observed to experience functional difficulty due to symptoms of both
conditions,21,24 with many patients having two or
more problem areas in functioning. This is particularly problematic given that these conditions can
occur during critical periods of social and academic
development for youth, where interference from
these conditions can lead to missing out on critical
experiences which may affect optimal functioning in
adulthood (eg, reduced access to social and academic
opportunities can lead to difficulty in vocational and
social functioning as adults due reduced experiences
of age appropriate norms). For example, a child with
OCD may have compulsions getting in the way of
completing school assignments, or a child with vocal
tics may have difficulty practicing reading aloud
before the class or speaking to the teacher, and children with both conditions may experience distraction due to obsessions or premonitory urges that can
interfere with concentration inside and outside of the
classroom.
Neurobiological research of OCD has focused on
the orbitofrontal cortex (along with the amygdala) in
a fear learning model. Although its etiology is multidetermined, OCD has a genetic component, with
increased risk of familial transmissionand some
observed genetic loci of interest that merit further
investigation.29–36 Additionally, alterations in glutamatergic functioning may also be associated with
OCD.37 Other research foci in the development of OCD
haveimplicated fear learning,38 operant theory,39 cognitive theory,40 and sensitivity to negative affect.41
Tic disorders are associated with dysfunction of
the prefrontal cortex and the basal ganglia along with
the limbic system.42,43 Androgens have been implicated in the childhood development of OCD and
CTDs, with empirical support provided by the elevated morbidity rate of both conditions in early youth
as well as the study of androgen roles in CTDs. Tic
disorders also have a genetic basis, with increased
risk observed in family members of probands who
experience tics.44,45 Research on genetic inheritance
for both conditions indicate polygenetic influences
with some overlap.46 Environmental risks for OCD/
CTDs have also been identified such as perinatal
difficulties,47 traumatic experiences,48,49 and immune
related risks.7,50–54
Journal of Central Nervous System Disease 2011:3
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A variety of orally administered pharmacotherapies
have demonstrated efficacy for youth with OCD and
CTDs, each with specific benefits and risks. The purpose of this review is to delineate medication options
based on clinical research, with randomized clinical
trial (RCT) evidence being weighted most highly followed by open trial evidence, with case reports and
other uncontrolled research holding less influence.
Controlled evidence is particularly pertinent for tic
disorders, as tic severity may fluctuate over relatively brief periods of time.55–57 An appropriate control group is necessary to separate medication effect
from a naturalistic course. Emphasis is placed on
the efficacy, safety, tolerability, and relative place in
evidence based support of these agents. Empirical
work was included if the predominant focus of the
research was on children; exceptions were made only
in the case of lack of pediatric research for a particular agent, and such research with an adult focus has
been specifically identified. While there is little evidence to indicate that OCD and CTDs present with
substantial differences between children and adults
that affect treatment decision making, the evidence
base for pharmacotherapy is more robust for adults.
The majority of medications indicated for children
have also been shown efficacious with adults, and
any substantial discrepancies are explicitly noted.
Psychopharmacological research for OCD and CTDs
is first addressed separately for each respective condition, with subsequent focus on issues in the clinical
management of each condition both individually as
well as in the context of comorbidity. While cognitive
behavioral therapy (CBT) has also been established
as efficacious for pediatric OCD and habit reversal
training has strong support for treating childhood
CTDs,58,59 the focus of this review is on pharmacotherapy, and behavioral therapies are discussed only
in the context of available treatment options in deciding on medication selection.

Pharmacotherapy Options
for the Treatment of Pediatric OCD

Selective reuptake inhibitor (SRI) medications have
received the majority of research with pediatric OCD,
which encompass the selective serotonin reuptake
inhibitors (SSRIs) and a specific tricyclic antidepressant (clomipramine), and over 1,000 patients
are now available for comparison in meta-analysis.
Journal of Central Nervous System Disease 2011:3

Meta-analysis of RCTs have indicated that these
medications have a significant effect relative to placebo, with overall effect size estimates ranging from
0.46–0.48, and with clomipramine showing a significant advantage over SSRIs in efficacy relative
to placebo.60,61 However, head to head comparisons
between clomipramine and SSRIs in a single trial are
unavailable, and variables in study design and subject selection can influence effect sizes. Additionally,
other factors (such as tolerability) have implications
for treatment selection.
Evidence for the use of SRIs in pediatric OCD
has been most conclusively demonstrated through
RCTs,62–72 which have demonstrated efficacy for clomipramine, sertraline, fluoxetine, fluvoxamine and
paroxetine (with pooled RCT effect sizes for each
medication observed to be 0.85, 0.47, 0.51, 0.31,
and 0.44, respectively).61 With regard to prescriptive
use for children, the United States Food and Drug
Administration (FDA) has provided approval for
pediatric OCD treatment for clomipramine (ages 10
and above), sertraline (ages 6 and above), fluoxetine
(ages 7 and above), and fluvoxamine (ages 8 and
above). For each of these medications, dosing titration using the lowest recommended dose with incremental increases every 2–4 weeks based on efficacy
and tolerability is recommended. Frequent visits at
treatment initiation are also recommended, followed
by less frequent monitoring after the medication regimen is stabilized.73

Selective Serotonin Reuptake
Inhibitors (SSRIs)

Among FDA approved SSRIs for pediatric OCD, no
significant efficacy differences have been observed,60,61
and no direct comparisons have been made in the
context of a single trial. Thus, choice of agent usage
is relegated to preferred half-life, observed patient
response, and idiographic tolerability of an individual agent, as the SSRIs do differ from one another in
pharmacodynamics and drug interactions. In pediatric OCD trials, more commonly reported side effects
of SSRIs include abdominal discomfort, decreased
appetite, sleep interference in the form of either
insomnia or somnolence, and fatigue.67,68,74,75 While
these side effects are not commonly prohibitive, significant patient dropout (22%) attributable to side
effects has been observed in pediatric OCD trials.61
127
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The FDA Black Box warning for suicidality for
SSRIs has addressed concern regarding the administration of SSRI medications,76,77 which was based on
a compilation analysis of data from RCTs in children
with depression and anxiety disorders as well as on
lay testimony of perceived risks. The risk for suicidal behaviors are theorized to occur in the context
of behavioral activation,78 a phenomenon which can
involve agitation, hostility, restlessness, impulsivity,
emotional lability, and insomnia. These symptoms
are most often seen 1–9 days after a dose change,78,79
where younger children may be at higher risk from
activation syndrome (with particular focus placed on
mood and irritability).77,80 When considering SSRI
suicide risk by diagnosis, Bridge et al found no statistically significant increase in risk of suicidal thinking
or behavior when considering pediatric OCD SSRI
trials,81 where they found an increased risk difference
between SSRIs and placebo to be 0.5 and a number
needed to harm of 200. Nevertheless, while such risk
may have been higher in trials for depression relative
to those for OCD,81 providers must carefully monitor
for increased suicidal ideation when administering
SSRIs to children with OCD, especially considering the high comorbidity rate with depression,82–84
which sometimes may go undetected given the difficulties in diagnosing pediatric internalizing disorders.85 Managing activation can be accomplished by
titrating and adjusting doses slowly, using the minimum therapeutic dose, and/or changing to a different
medication.75 Additionally, practice parameters recommend the use of CBT alone in mild and moderate severity cases, and together with a SSRI in more
severe cases.72 The combination approach should be
considered given its efficacy and tolerability with
the additional benefit of reduced suicidal symptoms
reported in those receiving CBT + SSRI versus those
receiving only SSRI treatment.86

Clomipramine

Clomipramine was the first antidepressant to demonstrate efficacy in RCTs for pediatric OCD and
is FDA approved in treating youth with OCD ages
10 and older.67,68,71 It has demonstrated relatively
stronger effects in reducing obsessive-compulsive
symptoms than the SSRIs, with an estimated effect
size of 0.85 relative to placebo.61 Clomipramine
is a tricyclic antidepressant which exerts effects
128

on serotonin and norepinephrine, which may partially account for its increased efficacy relative to
the selective agents.60 When using clomipramine,
a baseline electrocardiogram (EKG) is indicated to
observe for cardiac arrhythmia, and further EKG
monitoring along with blood level monitoring of
medication levels is indicated. Other side effects
associated with clomipramine include dry mouth,
somnolence, dizziness, fatigue, tremor, weight gain,
and constipation.67,68 Thus, while clomipramine has
the strongest demonstrated efficacy among medications for pediatric OCD, it is often not indicated as
a first-line agent due to its side effects, with particular concern given to its relationship with cardiac
arrhythmia.60,87,88

Other Agents

Atypical antipsychotics have drawn the majority of
attention among other agents in treatment for OCD,
with particular attention given to their role in augmenting non- or partial-response to SRIs. Some data
support this practice among adults; one recent metaanalysis suggests such use to be considered after
12 weeks of incomplete response to two adequate
trials of SRI therapy.89 However, despite its frequent
use in youth, no methodologically rigorous data exist
regarding antipsychotic augmentation of SRI therapy
in youth with OCD beyond case reports.90,91 Additionally, there are concerning metabolic and cardiac
effects associated with antipsychotic use among
youth.92 Given the lack of RCT data and the risks of
associated adverse effects, this option should only be
considered after failure of appropriate CBT (of sufficient duration by a professional with expertise) and
when symptoms are severely impairing functioning. Further evidence beyond uncontrolled reports is
required to justify its use in youngsters with OCD.93
A new direction in augmenting agents involves the
glutamate modulators memantine and riluzole, which
have had open trial support for treatment resistant
OCD in youth,94–96 with promising results. While preliminary, these medications provide an alternative to
the traditional serotonin hypothesis in pharmacotherapy for pediatric OCD. Other glutamate modulators
such as n-acetylcysteine and glycine have been theorized to be of pharmaceutical use, but no evidence
currently exists to support their efficacy in pediatric
OCD.97
Journal of Central Nervous System Disease 2011:3
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Pharmacotherapy Options
for the Treatment of Pediatric
Chronic Tic Disorders

The two major classes of medication that have been
indicated as efficacious with pediatric chronic tic disorders are dopamine antagonists (typical and atypical), and alpha-2 agonists. While no meta-analytic
estimates exist with regard to the efficacy of these
agents, the effect sizes of antipsychotics relative to
placebo are larger than those for alpha-2 agonists.98–103
Given the unique pharmacodynamic and pharmacokinetic characteristics of these medications, treatment
choice is guided by weighing risks of adverse effect
profile versus expectancy of treatment response.

Typical Antipsychotics

Typical antipsychotics were the first medications to
display efficacy in controlled research for pediatric tic
disorders, and thus have the broadest evidence base.
The only medication with FDA approval for pediatric
CTDs is pimozide (ages 12 and older). Haloperidol
has a long history in the treatment of CTDs, with evidence stretching back 50 years.104 While RCTs have
demonstrated the efficacy of haloperidol in adults,105
controlled evidence in youth is lacking; one crossover trial failed to find efficacy relative to placebo
on the primary outcome measure,106 though secondary outcome measures of global functioning detected
overall improvement. Side effects that are frequently
reported include extrapyramidal symptoms, sedation/
drowsiness, weight gain, and increased prolactin
secretion. Dosage reduction can be used to manage these side effects. Side effects from typical
antipsychotics that can be serious include tardive
dyskinesia and neuroleptic malignant syndrome. For
CTDs, much lower doses are used than those used
for psychotic disorders. For this reason and perhaps
because of neurobiological differences, those with
CTDs appear to have low risk for tardive dyskinesia. Estimates of the risk of tardive dyskinesia in
children and adolescents treated for TD range from
1%–4.8%.107–110 However, the risk of such effects
increases with greater treatment duration and dosage,
may persist after treatment discontinuation.111,112
Pimozide, which is a less powerful antagonist of
norepinephrine than haloperidol, has been employed
in treatment for pediatric CTDs. Its efficacy has been
established in RCTs,106,113 with fewer adverse effects
Journal of Central Nervous System Disease 2011:3

than haloperidol. However, it still presents with
a substantial side effect profile including weight gain,
akathisia, acute dystonia, QTc prolongation, tardive
dyskinesia, and extrapyramidal effects.114 Given its
QTc effects, electrocardiograms at baseline, during
titration, and at regular intervals throughout treatment
are indicated. Additionally, interactions with antidepressant medications (which are commonly employed
with OCD, such as fluvoxamine) have been observed,
which presents substantial concern when working
with comorbid conditions.
Fluphenazine, which has antagonistic properties
for both D1 and D2 receptors, is better tolerated than
haloperidol with regard to sedation and extrapyramidal effects while showing similar efficacy to haloperidol in adults.115,116 However, controlled data in
youth are lacking. Despite its relatively more desirable side effect profile, fluphenazine still presents the
risks of traditional neuroleptic adverse effects including akathisia, tardive dyskinesia, and extrapyramidal
effects.

Atypical Antipsychotics (Second
Generation Antipsychotics)

The more recently introduced atypical antipsychotics have now garnered a substantial evidence base
with regard to efficacy for pediatric CTDs. The major
advantage of atypical antipsychotics is the reduced
risk of tardive dyskinesia and extrapyramidal symptoms associated with classic neuroleptics. However,
there are concerns about the safety and tolerability of
these medications, especially with regard to increased
levels of prolactin (with the exceptions of aripiprazole, quetiapine, and clozapine), sedation, and metabolic effects which can lead to elevated glucose levels,
increased appetite, and weight gain.117
The medication with the most research evidence
in treatment for CTDs is risperidone, with efficacy
demonstrated through four RCTs (effect sizes = 0.55–
1.0).98,118–120 However, risperidone has been associated with weight gain, increased prolactin levels, and
sedation/fatigue as common side effects.121 Nevertheless, the tolerability of risperidone has been considered preferable to that of traditional neuroleptics such
as haloperidol.103
Ziprasidone has 5HT-2 and D2 antagonistic properties along with norepinephrine and 5HT reuptake
inhibition. It has RCT evidence to demonstrate
129
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e fficacy relative to placebo (effect size = 0.76),100 but
merits EKG monitoring due to effects on QTc.92,122,123
Additionally, mild sedation has been observed.100
Thus, while it has been demonstrated as efficacious,
particular concern with regard to its effect on cardiac conduction raises caution when considering
its use. Additionally, while mild sedation has been
observed.100 It is perhaps the atypical antipsychotic
with the lowest weight gain profile.
Olanzapine has displayed efficacy in children
with CTDs in several open trials124–126 and one small
crossover trial.127 However, it has increased risk from
weight gain and metabolic effects relative to other
atypical antipsychotics.121,124,128 Thus, given its other
associated side effects such as sedation and increased
prolactin levels, consideration for its use in CTDs
should be made in the context of other available
medicinal and behavioral treatment options.
Aripiprazole is a D2 regulator (partial agonist/
antagonist), addressing hyperdopaminergic conditons
in the limbic system and hypodopaminergic condition in the frontal and prefrontal cortices.129 Multiple open trials have indicated improvement in CTD
symptoms,130–133 but controlled evidence in children
is currently lacking, although RCTs are underway.
Sedation, nausea, headache, agitation, and insomnia
have been observed as side effects; some weight gain
has been observed, but to a lesser degree than other
comparable agents.121,134
Quetiapine has empirical support from one open
label trial,135 but lacks RCT evidence to support its
use. It is a weaker D2 antagonist than comparable
medications, and thus its theoretical efficacy for
CTDs is questioned. Abdominal discomfort, gastrointestinal upset, somnolence, and weight gain have
been observed as common side effects.
Given the observed side effects of atypical antipsychotics, careful observation of adverse effects is
recommended. With regard to metabolic effects, the
American Diabetes Association has published monitoring guidelines for these agents.136 While these criteria have not been empirically validated, they provide
a starting point in evaluating metabolic side effects
with patients. Correll92 has recommended detailed
monitoring schedules that include testing for glucose,
lipids, and liver function at three months after treatment initiation and then every six months thereafter,
and to evaluate for sedation and weight gain at each
130

visit. Additionally, symptoms of elevated prolactin
can include menstrual interruption in females and
breast tenderness in males and females, and merit further inquiry upon observation. Proactive management
of such effects is recommended including adjusting
dosing, changing medications, and monitoring of
lifestyle habits (eg, appropriate diet and exercise).

Alpha-2 Agonists

The alpha-2 agonists clonidine and guanfacine have
demonstrated efficacy in treating pediatric CTDs.
While observed effect sizes in treating CTDs have
been lower than those for antipsychotics, the major
benefits of the alpha-2 agonists relative to antipsychotics is their reduced side effect profile (which
does not include metabolic interference or extrapyramidal symptoms) and their efficacy for comorbid
ADHD.137
Clonidine has demonstrated efficacy in RCTs for
CTDs (effect sizes = 0.26–0.57),101,118,138 with fewer
side effects than neuroleptic and atypical antipsychotic medication. Common side effects reported
with clonidine use include sedation, irritability,
headaches, and dry mouth. However, given its short
half-life, withdrawal symptoms such as temporary
increases in blood pressure and heart rate have been
reported.139,140 Thus, blood pressure and pulse should
be monitored at baseline and during titration, with
some recommendations for baseline and follow up
ECGs.141
Guanfacine is more highly selective for the alpha2-adrenergic receptors, which is hypothesized to be
the reason for its improved side effect profile relative to clonidine (with particular regard to sedation).
It also has a longer half-life than clonidine, reducing
the risk of withdrawal effects and permitting for more
convenient dosing (which can be limited to twice per
day). Efficacy of treatment for CTDs has been demonstrated for guanfacine through RCTs (effect sizes =
0.67–0.84), with one including comorbid ADHD.102
Although one study did not detect improvement over
placebo,142 it was limited by a small sample size, short
duration, and a floor effect due to mild baseline tic
severity.

Other Agents

The efficacy of the anticonvulsant topiramate was
recently supported through an RCT by Jankovic
Journal of Central Nervous System Disease 2011:3
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et al. (ES = 1.01),99 and has further support from
retrospective chart reviews.143 Like the alpha-2
agonists, topiramate has the advantage of no risk of
extrapyramidal side effects or weight gain relative to
typical or atypical antipsychotics. Common observed
side effects include somnolence, weight loss, and cognitive slowing. The anticonvulsant levetiracetam has
shown open-label evidence for improving tics;144,145
however, two small randomized crossover trials
did not detect a tic-reducing effect.101,146 Commonly
reported side effects include somnolence, headache,
dizziness, and asthenia. Significant agitation has also
been associated with levetiracetam use and suicidal
ideation has been observed in 1% of patients,147,148
which merits close monitoring for psychiatric adverse
events during administration.149
Mecamylamine is a nicotine receptor agonist
which has conflicting research support, where a retrospective case report series indicated some efficacy,150
but it did not demonstrate superiority to placebo in a
well-designed RCT.151 Nicotine (via gum or transdermal patch) as an augmentation strategy with haloperidol has been investigated, with open trial evidence
showing minor effects for CTDs,152 but an RCT did
not support its efficacy.151 Baclofen is an agent that
interacts with GABA to inhibit the release of various neurotransmitters (including glutamate), which
has support in a large open label trial,153 and a small
RCT indicated significant difference from placebo on
the CGI–Severity,154 but only near-significance on the
Yale Global Tic Severity Scale (YGTSS).155,156 For
very localized tics, botulinum toxin has been studied,
with some evidence from open trials.157,158 In an RCT,
botulinum toxin reduced number of tics per minute
as recorded on videotape, but patients did not report
perceived benefit.159 Additionally, although botulinum
toxin may display some effectiveness in addressing a
very localized tic (eg, facial grimacing), it does not
address the underlying psychopathology as tics may
simply be reassigned to different body parts,159 and
thus it should not be considered a common treatment
for a wide variety of tics.
Other agents that interact with the dopaminergic system include metoclopramide, tetrabenazene, tiapride,
sulpriride, and pergolide. Metaclopromide is a D2 antagonist which has traditionally been used for gastroesophageal reflux disease and as an anti-nausea agent, with
side effects that can include sedation, increased appetite,
Journal of Central Nervous System Disease 2011:3

and increased levels of prolactin, along with a risk of
tardive dyskinesia and extrapyramidal symptoms.160
Though it has a limited evidence base for CTDs, in
a small RCT it demonstrated efficacy compared to
placebo (effect size = 0.95).161 Tetrabenazine is a dopamine agonist that intercedes in dopamine reuptake,
which has case series and open trial support.162–164 Side
effects include sedation, depression, nausea, insomnia,
akathisia, and parkinsonism, and insomnia. Tiapride is
a benzamide that has some support through an RCT to
improve tics compared to placebo,165 with hyperprolactinemia, somnolence, and weight gain as side effects
of note. Sulpiride is similar to tiapride, and has some
support through retrospective studies to improve tics in
adults.166 The most common side effects reported were
sedation and depression, although tardive dyskinesia
was reported in a case report.167 Both sulpiride and
tiapride are available in Europe but not in the United
States. Pergolide interferes with dopamine release
and has been investigated for use in Parkinson’s disease. While efficacy compared to placebo has been
reported,168,169 pergolide has been associated with cardiac valve pathology in treatment for Parkinson’s disease and has been withdrawn from the United States
market.170,171

Choosing Among Pharmacotherapy
Options for Pediatric OCD and CTDs
Clinical management of pediatric
obsessive compulsive disorder

The main choices among pharmacotherapy options
for pediatric OCD include SSRIs and clomipramine.
While clomipramine has demonstrated modestly superior outcomes relative to SSRIs, its side effects (especially its cardiovascular effects) limit its frontline use.
Thus, SSRIs are most often used as first-line agents,
with clomipramine used only after unsuccessful SSRI
trials.87,88 Table 1 provides a visual comparison of
medications with RCT evidence for pediatric OCD.
Although pharmacotherapy has demonstrated modest
efficacy in the treatment of pediatric OCD, CBT with
exposure and response prevention (E/RP) has demonstrated strong efficacy in pediatric OCD treatment,
with meta-analytic results suggesting greater efficacy
than pharmacological monotherapy.60,61 Exposure with
response prevention has a more favorable side effect
profile than pharmacotherapy and directly addresses
131
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Demonstrated
efficacy
compared to
placebo and
fewer side effects
compared to
clomipramine

Most efficacious
medication for
pediatric OCD

Selective
Serotonin
Reuptake
Inhibitors

Tricyclic
Antidepressants

Increased side
effect profile,
need for EKG
and blood level
monitoring

Not as
efficacious as
clomipramine
for pediatric
OCD

Disadvantages

Geller et al60
Geller et al63
POTS72
March et al70
DeVeaughGeiss et al67
Flament
et al68
Leonard
et al17

Sertraline

Clomipramine

Liebowitz
et al64
Geller et al18
Riddle et al66
Riddle et al65

Supporting
research

Paroxetine

Fluvoxamine

Fluoxetine

Medication

Notes: aResponse rates calculated from multiple outcomes (eg, CY-BOCS,197 CGI-I154).

Advantages

Medication
class

Table 1. Controlled evidence for pharmacotherapy options in the treatment of pediatric OCD.

50–200 mg

25–200 mg

10–60 mg

50–200 mg

10–80 mg/
day

Dose
ranges
employed

5–8 weeks

12 weeks

10–16 weeks

10 weeks

8–16 weeks

Duration of
intervention

49%–57% treatment
response for medication,
25%–27% treatment
response for placebo
42% treatment response
formedication, 26%
treatment response for
placebo
47%–71% treatment
response formedication,
33%–41% treatment
response for placebo
42%–53% treatment
response for medication,
26%–37% treatment
response for placebo
58%–75% treatment
response for medication,
10%–17% response
for placebo

Outcomesa
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the behavioral nature of obsessions and compulsions;
CBT alone is considered the first line therapy for mild
and moderate cases while CBT with an SSRI is recommended for severe cases.72 Cognitive behavioral
therapy has been perceived as credible and effective
by parents of children seeking anxiety treatment,172
and there are some indications that parents may prefer psychotherapy to SSRI use.173 However, a subset
of children/families may be unwilling to participate
in CBT, adhere to CBT principles, or may have poor
insight into their symptoms, and pharmacotherapy
may be particularly indicated for these populations.
Another innovative treatment for pediatric OCD which
combines CBT and biological treatments involves the
use of D-cycloserine (DCS), a partial NMDA agonist
which is proposed to enhance CBT outcome through
facilitating fear extinction. While this is a relatively
new approach to combining biological and behavioral
approaches to OCD, DCS augmentation of CBT has
displayed efficacy relative to CBT augmentation with
pill placebo in children with OCD as well as other
adult anxiety disorders, including OCD.38,40,174–176
Generally, obsessive-compulsive symptoms remain
chronic without appropriate treatment,177,178 and thus
an intervention is recommended (in contrast to the
option of no treatment) which considers the functional impairment experienced in proportion to the
risk of adverse effects of the selected treatment.

Clinical management of pediatric chronic
tic disorders

The main choices among pharmacotherapy options
for pediatric CTDs include neuroleptics, atypical
antipsychotics, and alpha-2 agonists. While neuroleptics have the most robust evidence base with regard to
efficacy for pediatric CTDs, they also have a significant side effect profile. Thus, atypical antipsychotics and alpha-2 agonists have emerged as first-line
pharmacotherapy options for pediatric CTDs,103,179
with neuroleptics reserved for treatment refractory
cases with marked impairment. Like with medications for pediatric OCD, it is important to balance
side effects with efficacy and it is recommended to
increase dosages conservatively. Table 2 provides a
visual comparison of medications with RCT evidence
for pediatric CTDs.
For youth with CTDs, tics generally run a waxing
and waning course, with many youth experiencing
Journal of Central Nervous System Disease 2011:3

remission of tics by age 18.55,89 The majority of
remaining youth will continue to exhibit tics, albeit
with reduced severity compared to those experienced in childhood and adolescence, and a minority
will continue to experience sustained tic symptoms.
Given these observations, the option of no treatment
or behavioral therapy should be considered in the
context of presenting severity versus the side effects
of the medication employed, with particular consideration given to habit reversal training (HRT). The
central components of HRT involve creating awareness of premonitory urges in context and then implementing incompatible competing behaviors, such
as contracting the muscle opposite of the tic. For
example, a child may learn to identify that he has an
eye-blinking tic when sitting in class, become able
to identify it each time it happens, and then invoke a
response where he consciously uses his eye muscles
to hold his eyes open when feeling such an urge. Habit
reversal training was the central component of the
multi-site RCT for the Comprehensive Intervention
for Tics (CBIT), along with functional analysis and
relaxation training. In this large (N = 126), multi-site
RCT, the CBIT intervention displayed an effect size
of 0.68 relative to the control arm, with a reduction
in tic severity comparable to contemporary medicinal interventions.58 Additionally, at 6 month follow
up 87% of treatment responders contacted experienced continued benefit from the CBIT intervention.
However, most patients were on medications during
the trial and a head to head comparison of therapy to
medication, similar to the Pediatric OCD Treatment
Study (POTS)72 is needed. While CBIT is a promising
intervention, it may not be appropriate for younger
children and those with limited insight/motivation,
and outcomes may be affected by certain comorbidities that would impact self-monitoring (eg, ADHD).

Clinical management of common
comorbid conditions

Comorbid conditions in children present complexity in the context of therapeutic management for
clinicians. Unfortunately, comorbidity is the rule
rather than the exception in the clinical presentation of children with OCD and CTDs, and may be
associated with attenuated response and remission
rates.180–183 It has also been observed that with CTDs,
more impairment may be caused by the comorbid
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Advantages

Most robust
evidence base
in demonstrating
efficacy for tics

Indicated to be
as effective as
neuroleptics, with
little risk of tardive
dyskinesia and
extrapyramidal
symptoms

Demonstrated
as efficacious
compared to
placebo, reduced
side effect
profile relative
to neuroleptics
and atypical
antipsychotics

Recently
demonstrated
efficacy at a
level comparable

Medication
class

Neuroleptics
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Atypical
antipsychotics

Alpha-2
Agonists

Anticonvulsants

Less robust
evidence base with
regard to efficacy
and side effects

Reduced efficacy
compared to
neuroleptics
and atypical
antipsychotics

Side effect profile
includes metabolic
effects, sedation,
and prolactin
interference

Potential side
effects include
tardive dyskinesia
and extrapyramidal
symptoms

Disadvantages

Sallee et al100

Ziprasidone

Topiramate

Jankovic
et al99

Scahill
et al102

Guanfacine

25–200 mg

1.5–3 mg

Gaffney et al118 0.1-.4 mg
Du et al138
Hedderick
et al101

Clonidine

5–40 mg

Bruggeman
0.5–6 mg
et al106
Dion et al120
Gaffney et al118
Gilbert et al113
Scahill et al98

Risperidone

0.5–4 mg

Dose
range
employed

Sallee et al106
Bruggeman
et al119
Gilbert et al113

Supporting
research

Pimozide

Medication

Table 2. Controlled evidence for pharmacotherapy options in the treatment of pediatric tic disorders.

10 weeks

8 weeks

4–8 weeks

6 weeks

4–8 weeks

4–8 weeks

Duration

Significant
reduction of tics
compared to
placebo

Significant
reduction of tics
compared to
placebo

50%–69%
treatment
response for
medication,
47% treatment
response
for placebo

39% reduction
in tic symptoms
for medication,
16% symptom
reduction
for placebo

44%–63%
treatment
response for
medication,
6%–26%
treatment
response
for placebo

Shown to reduce
tic severity
compared to
placebo, mixed
results when
compared
against
risperidone

Outcomesa
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Preliminary
indications of
efficacy, provides
alternatives to
conventional
pharmacological
approaches

Other dopamine
antagonists

Limited evidence
base, undesirable
side effect profiles,
tiapride unavailable
in the United States

Limited evidence
for efficacy, does
not address
underlying
psychopathology,
tics may reassign
to different parts
of body

in pediatric tic
disorders

Nicolson et al161 5–40 mg

Metoclopromide

5–6 mg/kg
body wt

Varied dose,
but one only
injection

3 mg–60 mg

Eggers et al165

Marras et al159

Singer et al155

Tiapride

Botulinum
toxin

Baclofen

Notes: aResponse rates calculated from multiple outcomes (eg, YGTSS,156 CGI-I154).

Avoids adverse
events associated
with continued
medication
administration

Botulinum
toxin

to neuroleptics
and atypical
antipsychotics with
fewer reported side
effects

8 weeks

10 weeks

2 weeks

4 weeks

64% treatment
response for
medication, 15%
for placebo
group

Reduction of
tics observed
as assessed
by behavioral
evaluation in
a RCT

39% reduction
in number of
tics observed
for intervention
group, 6%
increase in
number of tics
observed for
placebo groups

Significant
improvement
in overall
impairment,
but no significant
reduction in
motor or vocal
tics
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conditions than the tics themselves.180 In the context
of pharmacotherapy, the presence of CTDs in children may substantially attenuate response to SSRIs
for children with OCD, where one study found a 75%
response rate for children with OCD only in comparison to a 53% rate for those children with OCD
who also present with tics,62 and another found nonsignificance relative to placebo in post-hoc analyses
for sertraline monotherapy in children with OCD
and comorbid tics.182 Moreover, this comorbidity
has been associated with a greater OCD relapse rate
following paroxetine treatment.62 Further complicating matters is the fact that OCD is often comorbid
with CTDs and depression,82–84 and CTDs are frequently comorbid with OCD and ADHD.184 Given
the high comorbidity rate found between OCD and
CTDs (as well as with other conditions), clinicians
often are faced with multiple decisions in treatment
planning for these comorbid conditions. In general,
the state of current psychopharmacological practice
when presented with comorbidity for children with
OCD and tics is to use the agent that is appropriate for each condition if pharmacotherapy is needed,
while considering the possible negative or positive effects that the agent may have on comorbid
conditions.179,185,186
The situation is simplified in pharmacotherapy for
OCD, where SSRIs can affect both OCD and depression/anxiety, and while they have not been observed
to help with CTDs, they have not been associated with
worsening of comorbid tics. On the other hand, with
regard to comorbid ADHD and CTDs, while there is
some evidence that stimulants may exacerbate tics and
anxiety in children with CTDs,187,188 a meta-analysis by
Bloch et al indicates that this effect may be dependent
on the specific agent and dosing,189 and one multisite
RCT found roughly equal tic increases when using
methylphenidate, clonidine, or placebo.190 Although
the issue of stimulants and CTDs presents with some
contrasting evidence, using clonidine or guanfacine to
address comorbid CTDs and ADHD simultaneously is
a consideration when choosing among pharmacotherapy options for these conditions. Additionally, there is
some evidence that risperidone and aripiprazole may
have positive effects on anxiety symptoms,185,186,191
which is hypothesized to be a consequence of their
action on 5HT receptors, and is a further consideration
when treating comorbid CTDs and OCD.
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Conclusion

The goal of this review has been to discuss the current
state of research on pharmacotherapy for pediatric
OCD and CTDs, to provide an overview for clinical
practice, and to demarcate current limitations in the
literature to identify future research directions. While
gains have been made in developing effective and
safe/tolerable pharmacotherapy options for pediatric
OCD and CTDs, much progress remains to be made.
While pharmacotherapy is associated with generally
positive treatment response, no current medication
consistently achieves the more stringent criterion of
symptom remission. Even with CBT for pediatric
OCD (the most efficacious intervention reviewed),
a significant proportion of children remain symptomatic following treatment.72,192 With regard to pediatric OCD, moving beyond the serotonin hypothesis
into other domains such as ascertaining the role of
glutamate may provide fertile ground for efficacy
gains. For CTDs, identifying and evaluating safe and
effective alternatives to neuroleptics and atypical
antipsychotics are indicated, with the use of alpha-2
agonists and topiramate as a starting point. Across
disorders, identifying moderators and mediators of
response and side effects is of critical importance
to facilitate treatment individualization. Identifying
which populations respond better to a certain medicine or which patient groups are less likely to experience side effects from a particular agent could assist
in improved idiographic care.
With regard to contemporary agents, more comparative work between medications in a randomized fashion could allow for direct comparisons of
efficacy and adverse event rates. Many medications
have demonstrated efficacy relative to placebo, and
for a new medication to be of incremental value, it
must be more efficacious or have better safety/tolerability than currently available agents, which is
a hypothesis that may be best tested in a RCT with
medications compared against one another. The evidence base is robust enough to move beyond the “nil
hypothesis”193 that pharmacotherapy is better than no
intervention at all, and to make further progress, the
benchmark in many cases may be efficacious contemporary agents.
One further consideration is that that these
medications are not prescribed in a vacuum, but are
administered in the context of integrated behavioral
Journal of Central Nervous System Disease 2011:3
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healthcare. Careful weighing of the benefits and risks
relative to the degree of impairment is of foremost
importance when employing medications is needed,
with particular regard given to available behavioral
interventions. Moreover, given side effects of some
agents, establishing a therapeutic relationship is of
substantial consequence in promoting adherence to the
intervention and comfort in reporting adverse events,
and can also serve to empower a patient’s decision
making in treatment and provide a source of support
to the patient in the face of functional interference.
Such a relationship, often defined as the “therapeutic
alliance”, has been indicated for further exploration
with pediatric psychopharmacology,194 and explains
a portion of outcome variance in pharmacotherapy
for adult depression as well as a variety of pediatric
psychotherapies. It is also important to consider the
family role with these conditions,195,196 with a particular focus on how the family may interact with the
child’s symptom presentation. For example, a family
may overly accommodate a child’s OCD symptoms
or be overly critical of a child’s CTD symptoms,
which can serve to worsen symptoms. In the presence of heterogeneity among family reactions to the
pathology, clinicians can foster a supportive but disciplined approach towards implementing the chosen
intervention.
Compared to only 25 years ago, a marked increase
in pharmacotherapy interventions have become available for children with OCD and CTDs to intervene
for these debilitating conditions. This has provided
an array of efficacious interventions for youth with
markedly reduced side effect profiles, although much
progress still remains to be made. Given this expansion of treatment options, the major decisions in
clinical pharmacotherapy come down to a balance of
efficacy and adverse effects in the context of functional impairment and available psychosocial interventions. Managing these variables in the context
of the evidence base for each approach will foster
improved child outcomes.
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